Shares of Hemostemix Inc. (CVE:HEM – Get Free Report) rose 29.4% during trading on Saturday . The company traded as high as C$0.11 and last traded at C$0.11. Approximately 602,760 shares traded hands during trading, an increase of 511% from the average daily volume of 98,700 shares. The stock had previously closed at C$0.09.
Hemostemix Price Performance
The company’s 50-day moving average price is C$0.09 and its two-hundred day moving average price is C$0.10. The company has a debt-to-equity ratio of -55.07, a current ratio of 0.04 and a quick ratio of 0.48. The company has a market capitalization of C$20.73 million, a P/E ratio of -4.07 and a beta of 1.25.
About Hemostemix
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia. The company also develops NCP-01, which is preclinical trial to evaluate effect on neuropathic pain and motor function recovery.
Further Reading
- Five stocks we like better than Hemostemix
- Elon Taking SpaceX Public! $100 Pre-IPO Opportunity!
- How a Family Trust May Be Able To Help Preserve Your Wealth
- A U.S. “birthright” claim worth trillions – activated quietly
- Executive Order 14330: Trump’s Biggest Yet
- NEW LAW: Congress Approves Setup For Digital Dollar?
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
